Citation

Finnerty CC, Jeschke MG, Qian WJ, Kaushal A, Xiao W, Liu T, Gritsenko MA, Moore RJ, Camp DG, Moldawer LL, Elson C, Schoenfeld D, Gamelli R, Gibran NS, Klein M, Arnoldo BD, Remick D, Smith RD, Davis R, Tompkins RG, Herndon DN. Crit. Care Med. 2013; 41(6): 1421-1434.

Affiliation

1Department of Surgery, University of Texas Medical Branch, and Shriners Hospitals for Children, Galveston, TX. 2Institute for Translational Sciences, Sealy Center for Molecular Medicine, University of Texas Medical Branch, Galveston, TX. 3Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre and Division of Plastic Surgery, University of Toronto, Toronto, ON, Canada. 4Biological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA. 5Stanford Genome Technology Center, Stanford University School of Medicine, Stanford, CA. 6Department of Surgery, University of Florida College of Medicine, Gainesville, FL. 7Department of Surgery, Massachusetts General Hospital, Shriners Hospital For Children, and Harvard Medical School, Boston, MA. 8Department of Surgery, Loyola University Stritch School of Medicine, Maywood, IL. 9Department of Surgery, University of Washington School of Medicine, Harborview Medical Center, Seattle, WA. 10Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX. 11Boston University School of Medicine, Boston, MA.

Copyright

(Copyright © 2013, Society of Critical Care Medicine, Publisher Lippincott Williams and Wilkins)

DOI

10.1097/CCM.0b013e31827c072e

PMID

23507713

Abstract

OBJECTIVES:: Emerging proteomics techniques can be used to establish proteomic outcome signatures and to identify candidate biomarkers for survival following traumatic injury. We applied high-resolution liquid chromatography-mass spectrometry and multiplex cytokine analysis to profile the plasma proteome of survivors and nonsurvivors of massive burn injury to determine the proteomic survival signature following a major burn injury. DESIGN:: Proteomic discovery study. SETTING:: Five burn hospitals across the United States. PATIENTS:: Thirty-two burn patients (16 nonsurvivors and 16 survivors), 19-89 years old, were admitted within 96 hours of injury to the participating hospitals with burns covering more than 20% of the total body surface area and required at least one surgical intervention. INTERVENTIONS:: None. MEASUREMENTS AND MAIN RESULTS:: We found differences in circulating levels of 43 proteins involved in the acute-phase response, hepatic signaling, the complement cascade, inflammation, and insulin resistance. Thirty-two of the proteins identified were not previously known to play a role in the response to burn. Interleukin-4, interleukin-8, granulocyte macrophage colony-stimulating factor, monocyte chemotactic protein-1, and β2-microglobulin correlated well with survival and may serve as clinical biomarkers. CONCLUSIONS:: These results demonstrate the utility of these techniques for establishing proteomic survival signatures and for use as a discovery tool to identify candidate biomarkers for survival. This is the first clinical application of a high-throughput, large-scale liquid chromatography-mass spectrometry-based quantitative plasma proteomic approach for biomarker discovery for the prediction of patient outcome following burn, trauma, or critical illness.

Language: en